PharmaCom BioVet, Inc. Announces Cancer Care Centers to Incorporate Significant Benefits of Lymphoma Blood Tests for Canine Canc
2008年11月19日 - 7:25AM
Marketwired
PharmaCom BioVet, Inc. (PINKSHEETS: PHMB). PharmaCom BioVet, Inc.
is pleased to announce the incorporation of PetScreen LTD into
their companion animal treatment centers and the benefits of
PetScreen, LTD's Lymphoma Blood Testing in the treatment of canine
cancer treatments.
PharmaCom BioVet, Inc. President and CEO, Gary Berthold has
confirmed plans to promote and incorporate current Lymphoma Blood
Testing programs developed by PetScreen LTD of Nottingham, UK into
its new canine cancer treatments centers. In a recent letter from
PetScreen LTD's CEO, Dr. Kevin Slater, the collaboration between
the two companies is seen as an important step forward in improving
cancer diagnosis and treatment for companion animals. "Lymphoma is
one of the most common forms of cancer in dogs and accounts for a
significant percentage of cancer deaths," Berthold noted. "The
Canine Lymphoma Blood Test procedure pioneered by PetScreen will
provide our treatment centers, and veterinarians everywhere, with a
very simple means of testing for the disease."
"The benefits are wide ranging and will aid in the screening,
diagnosis and monitoring of lymphoma treatments programs," Berthold
continued. "This process is highly valuable in tracking the
efficacy of various levels of treatment as well as the overall
results from radio pharmaceutical usage. Of equal importance is its
ability to provide vital information once a patient's cancer has
gone into remission. It will allow us to better determine how the
treatment worked and, consequently, how to replicate those
results," he added.
"Our recent collaboration with PetScreen LTD further enables us
to provide effective, state-of-the-art canine cancer treatment
programs within our treatment centers," offered Berthold. "Our goal
is to help lead the way towards the highest achievements possible
in cancer care for companion animals. One of the key factors in
attaining this goal is the formation of synergistic relationships
with professionals around the country and the world. With each
collaboration, we are working to assemble the best minds in the
field of cancer research and veterinary oncology. Combined with
leading edge technologies and procedures, such as Lymphoma Blood
Testing, our hope is to accelerate the progress towards optimum
treatment results and an eventual cure," he concluded.
PetScreen LTD, founded by Dr. Slater and Board Chairman,
Professor Graeme Radcliffe, was established to provide
veterinarians with improved testing methodologies in order to help
them make better diagnostic and treatment decisions for companion
animals with cancer. The company features a comprehensive range of
services and a growing cooperative network of industry
professionals.
PharmaCom BioVet, Inc. is the inspiration of Gary and Sharon
Berthold of Raleigh, NC. Avid Siberian Husky breeders and life-long
dog lovers, the Berthold's were driven to establish the company
following the loss of two of their most precious Siberian Huskies
to cancer. While researching medical remedies, they discovered a
growing nationwide demand for canine cancer care along with an
astonishing lack of effective treatment options. To address these
realities, they formed PharmaCom BioVet, Inc. to establish canine
cancer treatment centers around the country. These facilities will
link the brightest veterinary leaders with the latest oncology
technologies to offer the most advanced cancer treatment programs
available.
About PharmaCom BioVet, Inc.:
PharmaCom BioVet, Inc. is dedicated to advancing the veterinary
care industry for companion animals by establishing
state-of-the-art treatment centers for lymphoma and other forms of
cancer throughout the country. The purpose of these centers is to
help prolong the quality of life for companion animals with cancer
and pursue the potential for complete cure. These centers will also
operate under the philosophy of providing a compassionate care
environment for both companion animal patients and their owners.
For more information, please visit our website
www.PharmaComBioVet.com.
About PetScreen, LTD:
PetScreen LTD. is headquartered and operates laboratories in
Nottingham, England. Its purpose is to develop and apply new
technologies directed towards improving cancer diagnosis and
treatment in dogs and other companion animals. Their facilities
offer services such as Canine Lymphoma Blood Tests, which provide
veterinarians with a simple means of screening, diagnosis and
monitoring treatment of dogs with lymphoma. Their DCA program
(Directed Chemotherapy Assay) helps in determining the most
effective chemotherapy treatment for each individual canine cancer
patient. From their UK location, they have developed a network of
national and international collaborators to provide services and
support to the veterinary cancer patient. For more information,
please visit the website at www.pet-screen.com.
About IsoTherapeutics Group, LLC:
The mission of IsoTherapeutics Group, LLC is to develop novel
diagnostic and therapeutic agents for the treatment of severe
diseases. ITG both develops their own technologies as well as
partners with other companies to help develop pharmaceuticals. Of
special interest are radiopharmaceuticals for oncology. In house
expertise includes synthetic organic chemistry, chelation
chemistry, radiochemistry, diagnostic and therapeutic isotopes,
conjugation chemistry, pharmacokinetics, and small animal research
models. For more information, please visit our website
www.isotherapeutics.com.
DISCLOSURE:
"Safe Harbor" statement under the Private Securities Litigation
Reform Act of 1995: This press release contains forward-looking
statements that are subject to risk and uncertainties, including,
but not limited to, the impact of competitive products, product
demand, market acceptance risks, fluctuations in operating results,
political risk and other risks detailed from time to time in
PharmaCom BioVet, Inc.'s filings with the Securities and Exchange
Commission. These risks could cause PharmaCom BioVet, Inc.'s actual
results to differ materially from those expressed in any
forward-looking statements made by, or on behalf of, PharmaCom
BioVet, Inc.
Contact: Market Ideas, Inc. 877-295-3981 ext. 2
info@marketideasinc.com
PharmaCom BioVet (CE) (USOTC:PHMB)
過去 株価チャート
から 4 2024 まで 5 2024
PharmaCom BioVet (CE) (USOTC:PHMB)
過去 株価チャート
から 5 2023 まで 5 2024